Opportunity Alert – AC-160105-085 – QUINTILES-04
Date Sourced: March 5, 2016
Category: Customer Opportunity
Status: Active Discussion
Potential (High-Moderate-Low): High
Add to SFA (Y/N): Yes
Client Action Required (Y/N): No
Opportunity:
Quintiles works with many of the leading biopharmaceutical and other life
science companies. Their core clinical solutions and services that include
project management and clinical monitoring functions for conducting
multi-site Phase II-IV trials. This is a strategic pursuit given that
Quintiles has helped develop or commercialize 90% of the best-selling
pharma products, all of Top 30 Oncology products, and all of Top 30 CNS
products; and operates in 81 countries supporting 1,000+ oncology studies,
375+ pediatric studies, and 230+ rare disease studies.
Website: www.quintiles.com
Summary of Activities/Tasks:
1. March 7, 1016 – Contacted Susan Kozauer, Senior Medical Director,
Therapeutic Science and Strategy Unit with an invite to the CleverCap Med
Adherence CxO Briefing on March 22, 2016. Sarah Richerson, Deputy Head of
Neuroscience Center of Excellence Therapeutic & Specialty Business
Development responded requesting a personal briefing on CleverCap. .
2. March 9, 2016 – Call was setup with Sarah, Susan and Amir Kalali, Global
Head, Neuroscience Center of Excellence. Date scheduled: March 10th at 11
AM ET.
3. March 10, 2016 – Call was productive with qualified interest. Sarah is
interested in evaluating CleverCap in trails related to behavioral health.
Was drawn to the multi-modal engagement capabilities (e.g., cap indicators,
text messaging, etc.). Forwarded short deck and working to coordinate a
follow-up call/meeting.
Susan works in support of several clinical trial divisions and can
facilitate further introductions into Quintiles where subject med adherence
is of particular concern. She felt that oncology focused trials would be a
good fit.
Both credited CleverCap for aligning with existing behaviors; and not
requiring subjects to learn a new method for taking medications or
undertaking intrusive measures.
Amir had a scheduling conflict and could not make call, but RSVP’d for the
3/22 briefing.
Forward Statements and Guidance:
We are actively working to coordinate follow-on calls/meetings with
stakeholders within the neuroscience, therapeutic and specialty trial
units. More information is forth-coming. Additional Quintile stakeholders
are also being pursued (see other Opportunity Alerts).
End.
Return to Listing
COMMENT FORM.
Comments